Paul Robbins

Paul Robbins has a strong background in translational sciences and oncology. Paul is currently serving as the Vice President of Translational Sciences at Allogene Therapeutics since June 2023. Prior to this, they held the position of Vice President of Head of Translational Medicine at Instil Bio from February 2021 to April 2023. Paul Robbins also had an extensive tenure at Pfizer, where they served as a Senior Director of Translational Oncology from August 2015 to February 2021. Before that, they worked as a Principal Scientist at MedImmune/AstraZeneca from January 2010 to August 2015. Paul also held roles as a Senior Scientist at MedImmune from January 2010 to 2012. Prior to joining industry, Paul Robbins worked as a Director of Cancer Pharmacology and Cell Biology at Prolexys Pharmaceuticals from October 2002 to January 2010. Paul has a strong academic background, including experience as a Senior Research Scientist at Stanford University from 1999 to 2002 and as a Post-doctoral fellow from 1996 to 1999. Paul Robbins completed their doctoral studies at the University of Southern California Medical School/Children's Hospital Los Angeles from 1991 to 1995.

Paul Robbins earned their Ph.D. in Molecular Microbiology, Immunology, and Virology from the University of Southern California, where they studied from 1991 to 1996. Prior to this, they attended Stanford University, although specific details about their degree and field of study at Stanford are not provided.